Concepts (134)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antibodies, Neutralizing | 18 | 2022 | 303 | 2.910 |
Why?
|
| HIV Antibodies | 16 | 2021 | 247 | 2.650 |
Why?
|
| HIV Envelope Protein gp120 | 12 | 2020 | 104 | 2.080 |
Why?
|
| HIV-1 | 18 | 2020 | 1260 | 1.950 |
Why?
|
| Immune Evasion | 5 | 2022 | 31 | 1.950 |
Why?
|
| Epitopes | 11 | 2020 | 97 | 1.220 |
Why?
|
| Antibodies, Monoclonal | 8 | 2022 | 142 | 1.170 |
Why?
|
| Binding Sites, Antibody | 2 | 2017 | 8 | 1.100 |
Why?
|
| Integrins | 4 | 2020 | 9 | 1.090 |
Why?
|
| Neutralization Tests | 8 | 2022 | 108 | 1.040 |
Why?
|
| HIV Infections | 18 | 2021 | 5097 | 0.920 |
Why?
|
| Biological Products | 1 | 2022 | 7 | 0.820 |
Why?
|
| CD4 Antigens | 4 | 2017 | 49 | 0.810 |
Why?
|
| Vaccines | 1 | 2022 | 86 | 0.740 |
Why?
|
| AIDS Vaccines | 7 | 2021 | 152 | 0.650 |
Why?
|
| Polysaccharides | 2 | 2016 | 45 | 0.630 |
Why?
|
| Virion | 1 | 2018 | 12 | 0.630 |
Why?
|
| Receptors, HIV | 1 | 2018 | 12 | 0.630 |
Why?
|
| HIV Envelope Protein gp41 | 2 | 2017 | 28 | 0.570 |
Why?
|
| HIV Antigens | 1 | 2017 | 26 | 0.550 |
Why?
|
| Humans | 25 | 2022 | 14537 | 0.510 |
Why?
|
| HIV Envelope Protein gp160 | 3 | 2020 | 22 | 0.450 |
Why?
|
| Spike Glycoprotein, Coronavirus | 6 | 2022 | 101 | 0.400 |
Why?
|
| Antibodies, Viral | 4 | 2022 | 284 | 0.400 |
Why?
|
| Antibody Specificity | 4 | 2020 | 30 | 0.390 |
Why?
|
| Immunoglobulin G | 2 | 2022 | 231 | 0.340 |
Why?
|
| Immunogenicity, Vaccine | 2 | 2021 | 103 | 0.340 |
Why?
|
| Cross Reactions | 5 | 2021 | 44 | 0.330 |
Why?
|
| Animals | 5 | 2022 | 1081 | 0.310 |
Why?
|
| B-Lymphocytes | 4 | 2016 | 34 | 0.280 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 2 | 2020 | 52 | 0.280 |
Why?
|
| Crystallography, X-Ray | 2 | 2017 | 12 | 0.280 |
Why?
|
| Protein Binding | 4 | 2018 | 62 | 0.260 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2020 | 151 | 0.250 |
Why?
|
| Binding Sites | 4 | 2018 | 43 | 0.250 |
Why?
|
| Adenoviridae | 2 | 2021 | 39 | 0.230 |
Why?
|
| Phylogeny | 2 | 2022 | 231 | 0.220 |
Why?
|
| Models, Molecular | 6 | 2022 | 84 | 0.210 |
Why?
|
| Mutation | 2 | 2022 | 306 | 0.210 |
Why?
|
| Horses | 1 | 2022 | 4 | 0.210 |
Why?
|
| Blood Donors | 2 | 2021 | 19 | 0.210 |
Why?
|
| Antiviral Agents | 1 | 2022 | 111 | 0.190 |
Why?
|
| Phylogeography | 1 | 2021 | 15 | 0.190 |
Why?
|
| Protein Conformation | 2 | 2018 | 24 | 0.180 |
Why?
|
| Immunoglobulin A | 1 | 2021 | 39 | 0.180 |
Why?
|
| Cell Line, Tumor | 2 | 2018 | 71 | 0.180 |
Why?
|
| Immunization, Secondary | 1 | 2021 | 72 | 0.180 |
Why?
|
| DNA, Viral | 1 | 2021 | 165 | 0.170 |
Why?
|
| Immunization | 1 | 2020 | 63 | 0.170 |
Why?
|
| Single-Chain Antibodies | 1 | 2020 | 5 | 0.170 |
Why?
|
| Host-Pathogen Interactions | 2 | 2020 | 24 | 0.170 |
Why?
|
| Complementarity Determining Regions | 2 | 2017 | 11 | 0.170 |
Why?
|
| Lysine | 1 | 2018 | 5 | 0.160 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2018 | 9 | 0.160 |
Why?
|
| Cell Line | 2 | 2016 | 93 | 0.160 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2018 | 8 | 0.160 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2018 | 36 | 0.160 |
Why?
|
| Disease Transmission, Infectious | 1 | 2017 | 39 | 0.140 |
Why?
|
| HeLa Cells | 1 | 2017 | 15 | 0.140 |
Why?
|
| Glycosylation | 1 | 2017 | 17 | 0.140 |
Why?
|
| Antibodies, Blocking | 1 | 2016 | 9 | 0.140 |
Why?
|
| HEK293 Cells | 1 | 2016 | 39 | 0.140 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 73 | 0.140 |
Why?
|
| Communicable Disease Control | 1 | 2017 | 101 | 0.130 |
Why?
|
| Epitopes, B-Lymphocyte | 2 | 2014 | 7 | 0.120 |
Why?
|
| Virus Replication | 1 | 2015 | 88 | 0.120 |
Why?
|
| Epitope Mapping | 4 | 2015 | 32 | 0.100 |
Why?
|
| Female | 6 | 2020 | 9103 | 0.100 |
Why?
|
| Time Factors | 3 | 2021 | 507 | 0.100 |
Why?
|
| Aptamers, Nucleotide | 1 | 2012 | 3 | 0.100 |
Why?
|
| Virus Internalization | 1 | 2012 | 5 | 0.100 |
Why?
|
| HIV Fusion Inhibitors | 1 | 2012 | 5 | 0.100 |
Why?
|
| Evolution, Molecular | 3 | 2021 | 60 | 0.100 |
Why?
|
| Amino Acid Sequence | 3 | 2018 | 139 | 0.090 |
Why?
|
| Macaca mulatta | 2 | 2021 | 14 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2013 | 967 | 0.090 |
Why?
|
| Simian Immunodeficiency Virus | 2 | 2020 | 8 | 0.080 |
Why?
|
| HIV | 1 | 2012 | 380 | 0.080 |
Why?
|
| Molecular Sequence Data | 3 | 2015 | 263 | 0.080 |
Why?
|
| Viral Load | 1 | 2011 | 819 | 0.070 |
Why?
|
| South Africa | 4 | 2022 | 7596 | 0.070 |
Why?
|
| Botswana | 1 | 2022 | 24 | 0.050 |
Why?
|
| Recombination, Genetic | 1 | 2022 | 27 | 0.050 |
Why?
|
| Mice | 1 | 2022 | 135 | 0.050 |
Why?
|
| Genetic Fitness | 1 | 2021 | 7 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 34 | 0.050 |
Why?
|
| Vaccine Potency | 1 | 2021 | 16 | 0.050 |
Why?
|
| Selection, Genetic | 1 | 2021 | 31 | 0.050 |
Why?
|
| Protein Domains | 1 | 2020 | 10 | 0.050 |
Why?
|
| Tretinoin | 1 | 2020 | 8 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2020 | 40 | 0.050 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 65 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2020 | 45 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2020 | 33 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2021 | 175 | 0.040 |
Why?
|
| Rabbits | 1 | 2020 | 35 | 0.040 |
Why?
|
| Vaccines, DNA | 1 | 2020 | 11 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2021 | 272 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2020 | 42 | 0.040 |
Why?
|
| Male | 2 | 2021 | 6754 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2018 | 17 | 0.040 |
Why?
|
| Macaca | 1 | 2018 | 4 | 0.040 |
Why?
|
| SAIDS Vaccines | 1 | 2018 | 4 | 0.040 |
Why?
|
| Peptides | 1 | 2018 | 40 | 0.040 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2018 | 13 | 0.040 |
Why?
|
| Alleles | 1 | 2018 | 143 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2017 | 49 | 0.030 |
Why?
|
| Global Health | 1 | 2017 | 193 | 0.030 |
Why?
|
| Vaccination | 1 | 2018 | 365 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2015 | 19 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 181 | 0.030 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2014 | 4 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2014 | 4 | 0.030 |
Why?
|
| Antibody Affinity | 1 | 2014 | 11 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 22 | 0.030 |
Why?
|
| Young Adult | 1 | 2021 | 2498 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 442 | 0.030 |
Why?
|
| Adolescent | 1 | 2021 | 2985 | 0.030 |
Why?
|
| Computational Biology | 1 | 2013 | 44 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2012 | 14 | 0.030 |
Why?
|
| Middle Aged | 1 | 2021 | 3601 | 0.030 |
Why?
|
| Genome, Viral | 1 | 2012 | 64 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2012 | 20 | 0.020 |
Why?
|
| Point Mutation | 1 | 2012 | 16 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2012 | 79 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2012 | 60 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 125 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2015 | 1160 | 0.020 |
Why?
|
| Anti-HIV Agents | 1 | 2020 | 1324 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2011 | 15 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 150 | 0.020 |
Why?
|
| HIV Seropositivity | 1 | 2012 | 265 | 0.020 |
Why?
|
| Adult | 1 | 2021 | 5913 | 0.020 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 2009 | 9 | 0.020 |
Why?
|